Use of PTHrP antagonists for treating renal cell carcinoma

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7727526
APP PUB NO 20060003916A1
SERIAL NO

10520085

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention concerns the use of a PTHrP antagonist for preparing a pharmaceutical composition for treating renal cell carcinoma (RCC) in a mammal and in particular in a human subject. Advantageously, the invention is of particular interest for inhibiting or reducing tumour growth and/or metastasis formation in kidney cancer and its metastatic developments, in particular in the lung and the liver.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)PARIS
HOPITAUX UNIVERSITAIRES DE STRASBOURG1 PLACE DE L'HÔPITAL STRASBOURG 67000
UNIVERSITE LOUIS PASTEUR4 RUE BLAISE PASCAL STRASBOURG 67000

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Helwig, Jean-Jacques Schiltigheim, FR 1 3
Lang, Herve Strasbourg, FR 2 5
Massfelder, Thierry Witternheim, FR 1 3
Schordan, Eric Handschuheim, FR 3 3

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation